Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dewi Vernerey

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III TrialThierry André, Dewi Vernerey, Laurent Mineur, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2025
Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapyNicolas Cabrit, Maurice Cheugoua-Zanetsie, Jayne Tierney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction CarcinomaMatthieu Faron, Maurice Cheugoua-Zanetsie, Jayne Tierney, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2018
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III TrialThierry André, Dewi Vernerey, Laurent Mineur, et al.
The Lancet. Oncology|March 28, 2024
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 studyStefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2025
Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapyNicolas Cabrit, Maurice Cheugoua-Zanetsie, Jayne Tierney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2023
Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction CarcinomaMatthieu Faron, Maurice Cheugoua-Zanetsie, Jayne Tierney, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2020
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiativeRomain Cohen, Dewi Vernerey, Carine Bellera, et al.
Pageof 16